Sarepta Therapeutics, Inc. Free Cash Flow 2009–2025
Sarepta Therapeutics, Inc. reported $-307.45M of free cash flow for fiscal 2025. That was 10.3% higher than fiscal 2024. Compared with fiscal 2020, the change was -1317.0%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $-307.45M | +10.3% |
| FY 2024 | $-342.74M | +40.6% |
| FY 2023 | $-577.10M | -62.0% |
| FY 2022 | $-356.17M | +26.1% |
| FY 2021 | $-481.66M | -2006.5% |
| FY 2020 | $25.26M | +104.9% |
| FY 2019 | $-516.09M | -14.7% |
| FY 2018 | $-449.82M | -84.4% |
| FY 2017 | $-244.00M | +2.9% |
| FY 2016 | $-251.16M | -64.3% |
| FY 2015 | $-152.87M | +0.7% |
| FY 2014 | $-153.98M | -129.6% |
| FY 2013 | $-67.06M | -125.0% |
| FY 2012 | $-29.80M | -19.9% |
| FY 2011 | $-24.86M | -55.0% |
| FY 2010 | $-16.04M | -64.8% |
| FY 2009 | $-9.73M | — |
Source: Sarepta Therapeutics, Inc. SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open SRPT 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Sarepta Therapeutics, Inc. reported $-307.45M of free cash flow for fiscal 2025. That was 10.3% higher than fiscal 2024. Compared with fiscal 2020, the change was -1317.0%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Sarepta Therapeutics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeSarepta Therapeutics, Inc. — frequently asked questions
What is Sarepta Therapeutics, Inc.'s free cash flow?
Sarepta Therapeutics, Inc. (SRPT) reported free cash flow of $-307.45M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Sarepta Therapeutics, Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.